NIH Assembles Precision Medicine Panel

The US National Institutes of Health has formed a team of experts to begin the process of building President Obama’s Precision Medicine Initiative.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

JANE ADES, NHGRIPresident Barack Obama’s vision for a Precision Medicine Initiative, which he voiced in this year’s State of the Union address, is inching closer to realization. The National Institutes of Health (NIH) yesterday (March 30) announced that it has formed a panel of precision medicine experts and researchers versed in large clinical trials to take the first steps toward engendering the widespread public participation that a large-scale personalized medicine research effort will require.

The “Working Group of the Advisory Committee to the NIH Director,” as it will be called, will gather public comment, define the aims of such a large study, and help design the study. Obama called for $215 million to fund the initiative in his FY2016 budget proposal. If OKed by Congress, about $130 million of this would be slated for the recruitment and management of a group of 1 million volunteers who would share their medical, genetic, and biographical information with researchers. “Establishing a 1 million person cohort is an audacious endeavor,” NIH Director Francis Collins said in a statement. “But the results from studying such a large group of Americans will build the scientific evidence necessary for moving precision medicine from concept to reality. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies